Jiro Health has signed a multiyear content agreement with publisher Wolters Kluwer to integrate clinical evidence from ASCO’s JCO family of journals into Jiro’s Practice Intelligence platform.  

The platform combines real-world patient data with peer-reviewed medical evidence, allowing physicians to view clinical and financial performance information such as prescribing patterns, quality metrics, patient population insights, reimbursement rates, and preventable denial trends. Additionally, the platform, which launched less than a month ago, has a Consult feature that uses medical literature to help answer clinical questions.  

Oncology evidence in the platform is now enhanced with ASCO’s clinical practice guidelines, clinical trial findings, and other content matched to the clinician’s patient population and clinical questions. Users can also earn CME credit as they engage with the platform.  

"ASCO is the gold standard in oncology," said Greg Field, co-founder and CEO of Jiro. "Most platforms still put that knowledge behind a search bar. Jiro connects ASCO content to each clinician's own practice data, so the right evidence can surface when, or even before, it's needed. That changes the model from reactive to proactive." 

"Trusted, high-quality evidence is foundational to responsible innovation in clinical decision support," said Rafael Sidi, Senior Vice President and General Manager for Health Research at Wolters Kluwer Health. "By making authoritative journal content available through Jiro's platform, we are helping clinicians connect with relevant medical evidence more efficiently and bring trusted knowledge closer to the point of care. We're pleased to work with Jiro as they pioneer actionable and personalized AI oncology solutions to help clinicians at the front lines of cancer care." 

The company believes that combining ASCO guidelines and trusted articles on emerging evidence with real-world practice data can support more informed clinical decision-making in each disease setting.  

"In hematology, the pace of change is relentless: new agents, updated sequencing, shifting standards of care across a dozen malignancies," said Shaji Kumar, MD, a hematologist at Mayo Clinic and a member of Jiro's Clinician Advisory Board. "Staying current isn't a matter of motivation; it's a matter of bandwidth. Bringing ASCO content into Jiro changes that equation. The right evidence can reach you, shaped by the patients you're actually treating." 

On its website, Jiro acknowledges that the platform uses AI and machine learning technologies developed with and trained by physicians, but that its outputs are neither generated nor reviewed by a human. The company reminds users that they are responsible for reviewing, validating, and verifying all information provided by AI before using it in clinical practice.  

Jiro is HIPAA compliant and SOC 2 certified and is available free of charge to all verified clinicians in the United States.

ASCO AI in Oncology is published by Conexiant under a license arrangement with the American Society of Clinical Oncology, Inc. (ASCO^®). The ideas and opinions expressed in ASCO AI in Oncology do not necessarily reflect those of Conexiant or ASCO. For more information, see Policies.